Inmunidad híbrida de la vacuna SARS-CoV-2 después de la tercera dosis en trabajadores sanitarios

Introduction: Hybrid immunity is the immune response of people infected with COVID-19 who received the SARS-CoV-2 vaccine. This combination is more powerful than the immunity that is generated after vaccination or infection alone. Objective: To compare the hybrid immunity of the SARS-CoV-2 vaccine after the third doses in healthcare workers from a public hospital in Peru. Objective: To compare the hybrid immunity of the SARS-CoV-2 vaccine after the third doses in healthcare workers from a public hospital in Peru. Material and Methods: A prospective observational cohort study was conducted on health workers at the Carrion Hospital in Huancayo-Peru; a total of 174 participants completed the study. Quantitative monitoring of neutralizing antibodies (NAb) and immunoglobulin G (IgG) was achieved after the first, second, and third doses of vaccination and compared with the time of COVID-19 infection. Results: The average age was 39 years. The average NAb was 3736 U in participants who became infected with COVID-19 after the second vaccine, and with the third dose it was 3039 U. In the group not infected with COVID-19, the average NAb production after the second dose was 1102U (p=0.009), and with the third vaccine, it was 2782U (p=0.685). Conclusions: Hybrid immunity is significantly high after the second dose, with a non-significant increase after the third dose of the vaccine.